多菌株益生菌通过调节微生物组衍生的代谢物和血清素通路来缓解腹
Jin-Ju Jeong1, Yoo-Jeong Jin2, Raja Ganesan1
1Institute for Liver and Digestive Disease, College of Medicine, Hallym University, Chuncheon, Korea.
Probiotics and antimicrobial proteins
|March 12, 2024
概括
多种菌株益生菌,Sensi-Biome,通过调节肠道微生物群和代谢物,有效控制了大鼠的腹. 这种干预对微生物组-神经元轴产生了积极影响,改善了肠道健康并减少了炎症.
科学领域:
- 胃肠道学和微生物学
- 肠道微生物组研究研究
- 神经胃肠病学 神经胃肠病学
背景情况:
- 腹是与肠道失调相关的常见症状.
- 微生物组-神经元轴在肠道健康中起着至关重要的作用.
- 了解益生菌对腹的影响需要研究这个轴.
研究的目的:
- 评估多种菌株益生菌 (Sensi-Biome) 在治疗腹方面的疗效.
- 探索Sensi-Biome对肠道微生物和神经元轴的影响.
- 分析对腹相关参数,炎症和肠道代谢物的影响.
主要方法:
- 一个由4%的酸诱导的小鼠腹模型.
- 在不同度 (1x10^8到1x10^10 CFU/0.5毫升) 的Sensi-Biome施用.
- 分析便参数,炎症性细胞因子,肠道微生物群 (16S rRNA) 和肠道代谢学 (LC-Orbitrap MS).
主要成果:
- 在最高益生菌剂量组 (G3) 中,便水分,肠道运动速度和pH值显著恢复.
- 调节血清素水平和基酶表达的托,表明微生物组-神经元轴的功能得到改善.
- 增加了Firmicutes的相对丰度,改变了短链脂肪酸,并改善了equol和oleamide的水平.
结论:
- Sensi-Biome在控制腹方面表现出显著的有效性.
- 益生菌的作用包括调节肠道代谢物和血清素路径.
- 这些发现凸显了Sensi-Biome通过微生物组-神经元轴来管理腹的潜力.
更多相关视频
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
169
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
169
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
252
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
252
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
119
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
119
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
212
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
212
Drugs for Treatment of Constipation-Predominant IBS
163
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
163
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331


